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The Role of AMP-Activated Protein Kinase (AMPK) In 
Tumorigenesis 
Fei Han 
 
Advisory Professor: Hui-Kuan Lin, Ph.D. 
 
 
 
AMPK plays a central role in controlling cellular and whole body energy level. 
Increasing studies have also discovered the diverse function of AMPK in cancer, 
such as autophagy and mitochondria biogenesis. However, how AMPK promotes 
cancer progression is still not clear. Here, we show that AMPK is essential for 
EGF-induced Akt activation, Glut1 expression, and glucose uptake.  AMPK is 
also required for various stresses induced Akt activation and promote cell 
survival, including hypoxia and glucose deprivation. In addition, we found glucose 
deprivation-induced VEGF expression and secretion is also depend on AMPK, 
which may contribute to angiogenesis of surrounding endothelial cell in the tumor 
microenvironment. We also discovered that AMPK directly phosphorylates Skp2 
at S256 residue and this phosphorylation is essential for Skp2 SCF complex 
integrity and E3 ligase activity to ubiquitinate Akt, which is critical for Akt 
activation. Also, Skp2 S256 phosphorylation can be induced by many stress and 
EGF. The phosphorylation status is necessary for breast cancer tumor 
progression and correlated with poor survival of breast cancer patient. 
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INTRODUCTION 
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1.1 Ubiquitination and Skp2-SCF complex 
      Ubiquitination is a post-translational modification that marks a protein with 
ubiquitin, a widely distributed small protein in cells. The process is conducted by 
three main enzymes: E1, E2, and E3. E1 is an ubiquitin activating enzyme that 
links ubiquitin with a thio-easter bond. The ubiquitin is then transferred by E2 to a 
substrate on the lysine residue. The different linkage of ubiquitin usually 
contributes to the diverse outcome. K48-linked ubiquitination will mark protein for 
ubiquitination-dependent proteasome degradation, while K63-linked 
ubiquitination is usually activating signaling. The substrate specificity is 
determined by E3. E3 can be either a single protein or have multiple subunits, 
such as the SCF complex. The main biological function of the SCF complex 
(Skp1, Cullins, F-box proteins) is to target protein for degradation by 
ubiquitination. It controls DNA replication, cell cycle progression, as well as signal 
transduction. The complex consists of a scaffold protein Cullin, an RING-
containing enzyme Rbx1/2, an adaptor F-box protein and Skp1 (Berndsen and 
Wolberger, 2014). Cul1 acts as a scaffold protein to link Skp1 and Rbx1. C-
terminal of Skp1 also bridges N-terminal of F-box protein, which determines the 
substrate specificity. There are 69 F-box proteins in human (Lee and Diehl, 2014), 
but only a few F-box proteins had been studied in detail. The most studied F-box 
proteins are β-TrCP and Skp2. The ubiquitination triggers by Skp2-SCF complex 
is displayed in Figure 1-1. The ubiquitination-dependent degradation of p27 was 
triggered mainly by Skp2. Skp2 null mice have small body size and weight but 
mice with double knockout of p27 and Skp2 could rescue MEFs cell growth 
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which is much slower in Skp2 null mice. Moreover, Skp2 and p27 expression 
were inversely correlated in multiple cancer patients with poor prognosis (Chan 
et al., 2010; Frescas and Pagano, 2008). Skp2 also has a non-proteolytic 
function. Our group previously found that Skp2 co-activated RhoA transcription 
and promote metastasis. Skp2 also mediates K63-linked polyubiquitination of 
Nbs1, which is important for DNA damage induced by ATM activation. Moreover, 
Skp2 null mice were reported to have reduced the chance to develop obesity 
when fed in long-term high-fat diet, associated with insulin resistance and 
glucose intolerance (Sakai T 2007). Mechanisms are believed to be both p27 
dependent or independent.  
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Figure 1 Diagram of substrate ubiquitination triggered by Skp2-SCF 
complex. 
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1.2. Akt ubiquitination in growth factor-induced Akt activation  
         PI3K/Akt signaling plays an important role in tumor initiation and 
progression. It controls cell proliferation, metabolism, apoptosis and migration (E. 
Gonzalez 2009). It can be activated by a variety of extracellular signals like 
growth factors and cytokines. The activation of membrane receptors thus triggers 
numerous signal events which finally contribute to cell proliferation. After PI3K is 
activated, it catalyzes the phosphorylation of PI(4,5)P2 to form PI(3,4,5) P3, 
which then recruits Akt to the plasma membrane (LC. 2001). Akt binds to 
PI(3,4,5)P3 phospholipid via its N-terminal PH domain, which is required for 
being recruited to the cell plasma membrane (S. R. Datta 1999, LC. 2001).  After 
membrane recruitment, Akt is then phosphorylated by PDK1 at Thr308 in its 
activation loop of the kinase domain. The mTORC2 will also phosphorylate Akt at 
Ser473 located in the regulatory domain in the cytoplasm. Our group discovered 
Traf6 E3 ligase ubiquitinated Akt in response to IGF-1 treatment and Skp2 SCF 
complex is responsible for EGF-induced ubiquitination of Akt (Wei-Lei Yang 2009, 
Chia-Hsin Chan 2012).  Both Traf6 and Skp2 trigger K63-linked 
polyubiquitination and facilitate Akt membrane localization and activation as 
showed in Figure 1-2. Consistently, loss of Traf6 or Skp2 has tumor suppression 
effect in xenograft mouse model. However, except for IGF and EGF treatment, 
whether Akt polyubiquitination is a prerequisite for Akt phosphorylation in other 
contexts is still not fully addressed.  
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Figure 2 Akt ubiquitination is a common mode for IGF-1, EGF and HRG-
induced Akt membrane recruitment and activation. 
 
 
 
 
 
Chan et al., Cell (2012) 
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1.3 PI3K/Akt pathway in hypoxia 
During solid tumor progression, there is a portion of cells will be hypoxic since 
they are away from blood vessels and have limited oxygen supply. As showed in 
Figure 1-3, right in the center of the tumor, severe hypoxia usually leads to 
necrosis. However, moderate hypoxia near the center of the tumor will survive 
and promote angiogenesis and metastasis. Hypoxic tumor cells are also less 
sensitive to radio- and chemotherapy, since they are not actively cycling and the 
chemotherapy drug fails to reach to the hypoxic region. HIF1a is the major 
downstream transcription factor to mediate adaptive response under hypoxia. 
Limited oxygen will protect HIF1a from the von Hippel-Lindau protein (VHL)-
mediated ubiquitination and proteasome degradation, thereby stabilize HIF1a. 
HIF1a then binds to hypoxia responsive element (HRE) and mediates 
transcription of many downstream effectors, such as glucose transporter and 
VEGF. HIF1a is overexpressed in a variety of malignant cancers and acts as a 
prognostic parameter for aggressive tumor. Hypoxia response can be HIF1a 
dependent or independent. Many studies have suggested that PI3K/Akt pathway 
is enhanced by hypoxia. In rat phaeochromocytoma (PC12) cells, hypoxia 
induces Akt phosphorylation and increases its downstream GSK3b 
phosphorylation at the peak of 6 hours and can prolong up to 24 hours (Dana 
Beitner-Johnson 2001). A similar phenomenon is found in six head and neck 
squamous cell carcinoma (HNSCC) cell lines (Hanneke Stegeman 2012). 
Inhibition of Akt under hypoxia induces apoptosis. These evidence suggested 
that hypoxia may protect the cell from apoptosis through activating Akt pathway y. 
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However, the mechanism of how hypoxia activates Akt signaling is largely 
unknown.     
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Figure 3 Diagram shows the hypoxic tumor microenvironment. 
Figure is adopt and modified from 
http://mail.mc.pref.osaka.jp/omc2/eng/biochemistry.html 
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1.4. The structure of AMPK. 
            AMPK is an evolutionally conserved serine/ threonine kinase. It consists 
of three subunits: α, β, and γ (Davies SP 1994, K.I. Mitchelhill 1994). The 
catalytic α subunit has two isoforms: α1 and α2, which encoded by PRKAA1 and 
PRKAA2. Their expression varies in different cell types. The α1 isoform is 
expressed widely in heart, liver, lung, brain, spleen, etc. while the α2 isoform is 
more tissue-restricted, and mainly expressed in neuron and muscle cells (B. E. 
Crute 1998). The kinase domain is located in N-terminal of α subunit; allowing 
phosphorylation by upstream kinases. Five phosphorylation sites have been 
reported in the past few years:  Thr172, Ser173, Thr258 and Ser485/491 (Woods, 
Vertommen et al. 2003, Djouder, Tuerk et al. 2009). Threonine 172 is the major 
phosphorylation site induced under various situations and is required to fully 
activate downstream substrates, while Ser173, Ser485 on α1 subunit and Ser491 
on α2 subunit are autophosphorylated by PKA or Akt, which is believed to inhibit 
AMPK activity (Djouder, Tuerk et al. 2009). After the kinase domain, there is an 
autoinhibitory domain (AID) which binds and inhibits the kinase domain, followed 
by the β/γ interaction domain on the C-terminal. The reported constitutively 
activated form of AMPKα is the best evidence for the autoinhibitory domain (AID) 
function since it is a truncated form without C- terminal AID and β/γ interaction 
domain (Jaleel 2006).
11 
 
      The regulatory β subunits also have two isoforms: β1 and β2, which are 
encoded by PRKAB1 and PRKAB2. Similar to α subunit, the β1 isoform is also 
expressed ubiquitously but the β2 isoform is only expressed in skeletal muscle 
and heart (Chen 1999). The β subunits consist of a carbohydrate binding module 
(CBM), previously called glycogen binding domain (GBD) and a C-terminal 
sequence that bridges α/γ-subunits. It is also reported that a myristoylation site is 
located within the β subunits, which might contribute the membrane location of 
AMPK and increased ability of AMP to activate AMPK α subunit allosterically 
(Mitchelhill 1997, Oakhill JS 2010). The central carbohydrate binding motif binds 
the α1-6 linked branch glycogen instead of α1-4 linear glycogen and inhibits α 
subunit kinase domain allosterically. It provides an additional sensing mechanism 
of glycogen store besides ATP level (Koay 2007, McBride 2009). 
      The γ subunit is important to AMPK activation while cells encounter changes 
in ATP level. It has 3 transcriptional variants: γ1, γ2, and γ3. The γ1 isoform has 
331 residues and is most widely expressed. The 569 - residues γ2 subunit is 
majority expressed in the brain, heart, placenta and skeletal muscle. The isoform 
γ3 which composed of 489 residues is only expressed in skeletal muscle. The 
three isoforms are different in N-terminal sequence but what is common is that 
they all have a sequence to interact with α/β subunits and two Bateman domains. 
The two Bateman domains consist of four symmetric cystathionine β-synthetase 
(CBS) motifs, allowing four possible adenyl-binding sites (Mahlapuu 2004). The 
hydroxyl groups of AMP ribose interact with an aspartic acid residue on the α-
helix adjacent to the site. Binding of AMP instead of ATP to the CBS site will lead 
12 
 
to a conformational change in the kinase domain of α subunit, allowing upstream 
kinases interact with and phosphorylate AMPK Thr172. Except for AMP: ATP 
ratio sensing, cells can also sense ADP: ATP ratio by binding of ADP to γCBS 1 
and 3 and stimulating Thr172phosphorylation (Oakhill, Steel et al. 2011). A 
schematic picture of the heterotrimeric AMPK subunits is showed in Figure 1-4. 
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Figure 1-4 Schematic representation of AMPK α β γ subunits 
Various a, b, and c AMPK subunits and isoforms with important domains highlighted: 
Kinase domain, autoinhibitory domain (AID), β subunit interaction domain (β-SID), 
carbohydrate binding module (CBM), αγ subunits binding sequence (αγ SBS) 
cystathionine beta sheet (CBS) regions. 
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1.5. AMPK activation and hypoxia 
       There are two major upstream kinases for AMPK Thr172 phosphorylation: 
LKB1 and CaMKKβ. LKB1 was initially identified as a tumor-suppressor gene 
due to its inherited germline mutations to cause cancer-prone Peutz-Jeghers 
syndrome (Hemminki A 1998, Jenne DE 1998). LKB1 associates with STRAD, 
MO25 and functions as a complex. LKB1 activity is much weaker without other 
components in the complex (Hawley SA 2003). LKB1 tumor suppressor is 
commonly inactivated in lung and cervix cancers and thought to promote cancer 
progression. There is more than 20% of cervical cancer that harbors LKB1 
somatic mutations (Shana N. Wingo 2009). LKB1 as a master kinase for AMPK 
can also phosphorylate thirteen members in the AMPK superfamily, while the 
other 12 members cannot response to AMP (Lizcano JM 2004, Sakamoto K 
2004). Increasing evidence favors that LKB1 constitutively activates AMPK to 
maintain a basal AMPK function in normal physiological conditions. Muscle-
specific LKB1 KO mouse is reported to have impaired glucose uptake and 
AMPKα2 phosphorylation induced by AICAR or contraction (Sakamoto K 2005). 
A similar phenotype can be observed in liver LKB1 KO mice. Metformin-induced 
AMPK phosphorylation and glucose uptake is also impaired without LKB1 
expression in liver (Shaw RJ 2005). These LKB1 animal models suggest that 
LKB1 is the major kinase for AMPK in skeletal muscle and liver.  
      Ca2+/calmodulin dependent kinase kinases (CaMKK) is found by two groups 
at the similar time as an alternative AMPK upstream kinase in the brain as well 
as in LKB1 deficient cells (Hawley SA 2005, Woods A 2005). However, CaMKK 
15 
 
is reported to share more similar sequence to yeast snf1/AMPK activating kinase 
than LKB1. It suggests CaMKKβ might be more specific to AMPK but not the 
other members of AMPK superfamily. There are three snf1-activating kinases in 
yeast: Pak1, Tos3, and Elm1. CaMKK overexpression can restore snf1 activity 
and phenotype in the deletion of Pak1, Tos3, and Elm1 cells in yeast. It can also 
phosphorylate yeast snf1 in vitro (Seung-Pyo Hong 2005). All these evidence 
strengthened that CaMKK is the also a major AMPK kinase, which might function 
in other cell types. Unlike LKB1 which activates AMPK through lower AMP: ATP 
ratio, CaMKKβ activates AMPK through changed intercellular Ca2+ levels 
independently of ATP levels. Both of LKB1 and CaMKK may act synergistically or 
independently in different contexts.  
         There are many physiological processes, stressor, and compounds that 
can alter AMPK activity. The compound that can activate or inhibit AMPK 
activation is listed in Table 1-1. The activation mode is either through changes in 
AMP/ATP ratio or intercellular Ca2+ level. Hypoxia is also reported to activate 
AMPK through ROS-mediated ER calcium release and calcium release-activated 
calcium (CRAC) channels activation, which all contributes to intercellular Ca2+ 
increase and CaMKKβ activation. Knockdown of CaMKKβ abolished AMPK 
activation under hypoxia (Brooke M. Emerling 2009, Mungai PT 2011).  
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Table 1-1 List of compounds and mode of AMPK activation/inhibition 
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1.6 Downstream substrates and potential oncogenic function of AMPK 
     AMPK mediates numerous cellular functions through diverse downstream 
substrates. As described above, AMPK is a master regulator of metabolism.  The 
first identified downstream substrate is ACC. AMPK directly phosphorylates ACC 
and inhibits its function in lipogenesis. AMPK increases energy levels by 
stimulating fatty acid oxidation. Specifically, AMPK phosphorylates ACC1 at  
residue Ser79 and ACC2 at Ser212 (Hardie DG 2002). ACC converts acetyl CoA 
to malonyl CoA and promotes lipid synthesis (Hardie DG 2002). Malonyl coA 
inhibits CPT1b to block fatty acid transport to mitochondria for β-oxidation (Mills 
SE 1983). AMPK phosphorylates ACC to keep it inactive, thereby decreasing the 
rate of fatty acid synthesis and promoting fatty acid oxidation to generate more 
ATP and fulfill the cellular requirement of energy.  
         For roles in the glucose metabolism, AMPK is reported to increase glucose 
uptake and affect Glut4 membrane translocation in skeletal muscle (Kurth-
Kraczek EJ 1999). It directly phosphorylates TBC1D1/4, a Rab GTPase 
activating protein believed to associate and attenuate Glut4 translocation(Taylor 
EB 2008). However, there are still many unaddressed questions about how 
AMPK regulates glucose uptake. AMPK also reduces glycogen synthesis through 
phosphorylating and inhibiting glycogen synthase at Ser7 and promoting 
glycolysis by phosphorylating PFK2 on Ser466(Marsin AS 2000).  PFK2 is 
responsible for converting fructose 6 phosphate to fructose 2, 6-biophosphate in 
the glycolysis pathway. Therefore, AMPK increases ATP production by activating 
glucose uptake and glycolysis in the muscle cell. 
18 
 
           AMPK also phosphorylates TSC2 and raptor to block the mTOR pathway 
and reduce protein synthesis (Inoki K 2003, Gwinn DM 2008). AMPK indirectly 
inhibits the mTOR pathway and also leads to changes in transcription process 
thus affecting many cellular functions, for example, autophagy. Also, AMPK 
directly phosphorylates ULK to promote autophagy when cells have limited 
nutrient (Egan DF 2011).   
        Except for the cytoplasm, AMPK is also located in the nucleus and 
phosphorylates HDAC at Ser259 and Ser498. Phosphorylation of HDAC 
dissociates it from MEF2 and 14-3-3 protein, which in turn lead to HDAC nuclear 
export (McGee SL 2008). The release of HDAC5 from the nucleus increased 
histone acetylation and recruited other transcription factors like PGC-1α to Glut4 
promoter (Michael LF 2001). An HDAC5 phosphorylation-deficient mutant has a 
less Glut4 expression, which might be another mechanism of how AMPK 
regulates glucose uptake. Recently, AMPK is reported to phosphorylate YAP at 
Ser94 and inactivate YAP function by disassociating it with 14-3-3 and promoting 
its cytoplasm sequestration. Therefore, AMPK negatively regulates YAP-Hippo 
pathway under energy stress (Jung-Soon Mo 2015). 
         Tumor cells need to adjust their metabolism to generate energy to support 
constant cell division in stressed conditions, such as hypoxia and nutrient 
deprivation (DeBerardinis RJ 2008). AMPK promotes metabolic adaptation 
during tumor growth. During energy stress, the generation of NADPH by the 
pentose phosphate pathway is impaired. AMPK phosphorylates ACC and inhibits 
fatty acid synthesis. The NADPH level will be stabilized because of the 
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decreased consumption in the fatty-acid synthesis and increased NADPH 
synthesis rate by fatty acid oxidation. At low intracellular ATP levels, AMPK 
activation induces alternative routes for NADPH production in order to balance 
NADPH homeostasis (Jeon SM 2012). In addition, AMPK also activates the 
eukaryotic elongation factor 2 kinase (eEF2K), which promotes cell survival 
under nutrient depletion by blocking translation elongation (Leprivier G 2013). In 
aggressive breast cancers, AMPK activation increases tumor glucose 
metabolism by increasing glycolysis, as well as the non-oxidative pentose 
phosphate cycle (Laderoute KR 2014). Hypoxia-induced AMPK activation is 
reported to regulate autophagy and may contribute to cell survival in prostate 
cancer(Rishi Raj Chhipa 2011). 
 
1.7 Rationale 
Hypoxia plays a critical role in radio- and chemoresistance, angiogenesis, and 
metastasis. It also activates Akt signaling to promote cell survival. However, how 
cells sense the oxygen and activate Akt is largely unknown. The sensing 
mechanism could start from membrane receptors/ channels, nuclear DNA 
damage, mitochondria or other reported stress kinases such as JNK or AMPK. 
We could screen many stress-related kinases that might be upstream of Akt 
activation. Since AMPK is reported to be activated by hypoxia through 
mitochondria ROS and it also shares many substrates with Akt, such as TSC, 
Foxo, and mTOR, it will be interesting to explore the possible links between 
AMPK and Akt under hypoxia. In addition, since Akt polyubiquitination is 
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important for IGF-1- and EGF-induced Akt phosphorylation, it may be also 
involved in hypoxia-induced Akt activation. Therefore, the dissertation is mainly 
focused on the questions that how Akt is activated, whether AMPK or other 
kinases are involved and whether Akt ubiquitination contributes its activity under 
hypoxia.  
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CHAPTER 2 
MATERIAL AND METHODS 
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2.1. Cell culture and reagents 
HEK293T, HEK293, MDA231, HUVEC cells were purchased from American 
Type Culture Collection. Skp2 WT and KO MEFs were prepared as previously 
described (Hui-Kuan Lin 2010). WT and AMPKa1/a2 knockout immortalized 
MEFs were from Dr. Kun-Liang Guan from the University of California, San Diego.  
HEK293 and HEK 293T cells were cultured in F12 medium supplemented with 
10% FBS. HUVEC cells were maintained in EGM-plus media from Lonza. All 
other cells were cultured in DMEM/high glucose medium supplemented with 10% 
FBS. Kinase inhibitor library was purchased from Selleck Chemicals cherry pick 
customized library. 2 NBDG used for glucose uptake assay is from Sigma, H2O2, 
compound C and STO609 is from Sigma as well. Plasmids: His6-ubiquitin (His-
Ub), pcDNA3-Flag-Skp2, pBabe-Skp2 constructs were previously described (Hui-
Kuan Lin 2010). Skp2 and Cul1 mutants were generated using site-direct 
mutagenesis. Primers for mutagenesis are listed in Table 2-1.  
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Table 2-1 Primers for site direct mutagenesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name Sequence
Skp2 S238A-F 5'-GCGACTTAACCTTGATGGGTGTTCTG
Skp2 S238A-R 5'-CAGAACACCCATCAAGGTTAAGTCGC
Skp2 S256A-F 5'-CTTTGCTAAGCAGCTGTGCCCAGACTGGATGAG
Skp2 S256A-R 5'-CTCATCCAGTCTGGCACAGCTGCTTAGCAAAG
Skp2 S256D-F 5'-GCTAAGCAGCTGATAGACTGGATGAG
Skp2 S256D-R 5'-CTCATCCAGTCTATCACAGCTGCTTAGC
Skp2 S367A-F 5'-GGATCCGGTTGGACGCTGACATCGGATGCCCTC
Skp2 S367A-R 5'-GAGGGCATCCGATGTCAGCGTCCAACCGGATCC
Skp2 S382/383A-F 5'-GAACTTCCAAACTCAAGGCCGCCCATAAGCTATTTTGC
Skp2 S382/383A-F 5'-GCAAAATAGCTTATGGGCGGCCTTGAGTTTGGAAGTTC
Cul1 K221R-F 5'-GATGATGCATTTGCACGGGGCCCTACGTTAACAG
Cul1 K221R-F 5'-CTGTTAAGGTAGGGCCCCGTGCAAATGCATCATC
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2.2. Immunoprecipitation and immunoblotting 
Cells were lysed in RIPA buffer (50mM Tris-HCI pH 7.4, 1% NP40, 0.5% Na-
deoxycholate, 0.1% SDS, 150mM NaCI, 2mM EDTA, and 50mM NaF). SDS 
sample buffer was added to the lysate for immunoblotting. For IP, Cells were 
lysed and quantified for protein concentration. The primary antibody was added 
and incubated in 4-degree rotation rack overnight. Protein A/G beads were then 
added for additional 3 hours followed by multiple wash step and immunoblotting. 
The following antibodies were used: anti-phosphor-Akt(T308), anti- phosphor-
Akt(S473), anti-phosphor-ACC, anti-phosphor-AMPKα, anti-phospho-GSK3β, 
anti-Akt, anti-AMPKα, anti-ACC, anti-GSK3β, anti-Cullin1 are all purchased from 
Cell Signaling Technology; anti-Ubiquitin, anti-Skp1 are from Santa Cruz; anti-HA, 
anti-Flag, anti-β actin are from Sigma; anti-CaMKKβ and anti-Glut1are from 
Abcam. The customed phosphor-Skp2 S256 antibody is from Jiaxing Xinda 
Biotechnology Co.,Ltd.  
 
2.3. In vitro kinase assay 
Recombinant GST-Skp2 WT, S256A, and S256D proteins were expressed in 
BL21 bacteria and purified with Glutathione beads. HA-AMPKα active and 
kinase-dead proteins were immunoprecipitated from 293T cells with HA antibody, 
and then elute with HA peptide.  Recombinant GST-Skp2  and HA- AMPKα were 
incubate for 30 minutes at 30oC in 20 μl of in vitro kinase reaction buffer (2mM 
DTT , 10mM MgCl2,  25mM Tris-HCl at pH 7.5, 0.1mM Na3VO4 and 5mM β-
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glycerophosphate, 0.5mM ATP). The reaction was stopped after indicated time 
by SDS sample buffer and subjected to immunoblotting analysis. 
 
2.4. Viral infection   
For AMPK, CaMKKβ, LKB1 and Skp2 knockdown, lentiviral packing plasmid and 
pLKO.1-puro-shRNA constructs (Sigma) were transfected into 293T cells using 
calcium phosphate method. After 36 hours, the supernatant was collected, and 
MDA231 parental cells were infected and 2µg/ml puromycin selected for a week. 
Knockdown efficiency was detected by western blot. For Skp2 WT, S256A and 
S256D restore cell, Skp2 was cloned into pLKO.1 vector (Sigma). Mutants were 
generated by site-direct mutagenesis. The lentiviral shRNAs (Sigma) for those 
genes are listed in Table 2-2 
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Table 2-2 Sequence of shRNAs 
 
 
 
 
 
 
 
 
 
 
 
 
 
shRNA Sequence
shLuc 5'-CGCTGAGTACTTCGAAATGTC
shSkp2-1 5'-GATAGTGTCATGCTAAAGAAT
shSkp2-2 5'-GCCTAAGCTAAATCGAGAGAA
shCaMKKβ 5'-CCGGGTGAAGACCATGATACGTAAACTCGAGTTTACGTATCATGGTCTTCACTTTTT
shLKB1 5'-CATCTACACTCAGGACTTCAC
shAMPKα1-1 5'-CCGGGTTGCCTACCATCTCATAATACTCGAGTATTATGAGATGGTAGGCAACTTTTT
shAMPKα1-2 5'-CCGGGTAGCTGTGAAGATACTCAATCTCGAGATTGAGTATCTTCACAGCTACTTTTTTG
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2.5. In Vivo Ubiquitination assay 
HEK293T cells were transfected with HA-Akt, His-Ub and Flag-Skp2 mutant 
plasmids. 48 hours later, cells were then lysed using high-stringency denaturing 
buffer (10mM imidazole, 0.1M Na2HPO4/NaH2PO4 at pH 8.0 and 6M guanidine-
HCl). 10% whole cell lysate was used as input control and the other 90% lysate 
was incubated the with nickel-agarose beads for 3 hours. Samples were washed 
carefully for four times and sample buffer is added to elute the protein binding on 
the nickel beads. Samples were then subjected to immunoblotting analysis with 
indicated antibody.  
 
2.6. Cell Survival Assay 
104 of cells were seeded in 12-well plates in triplicates and cultured for 24 hours 
before any treatment. For cell survival under glucose deprivation, the control 
group was treated with DMEM high glucose medium (10% FBS) and test group 
was treated with glucose-free medium (10% FBS) for 16 hours. Culture medium 
with the dead cell was collected and attached cells were also trypsinized and 
combined. Then all cells were centrifuged at 3000 rpm for 10 min. Supernatants 
were removed and 100μl PBS were added to each sample. Trypan blue was 
added to each sample at 1:10 ratio, then cells were resuspended and aliquot 
10μl of it were added into hematocounter for cell counting. The ratio of trypan 
blue stained and unstained cells were counted under a microscope. For cell 
survival rate under hypoxia, same cells were seeded with the control group in the 
incubator and test group in a hypoxia chamber (1% O2) for 72 hours. Viable cells 
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under both conditions were counted using the trypan blue exclusion assay under 
a microscope. 
 
2.7. Recombinant Protein Purification  
Recombinant GST-Skp2 (WT, S256A, and S256D) protein was expressed in 
BL21 bacteria by transformation and induced with IPTG for 18 hours at room 
temperature. The bacteria were lysed by sonication and subjected to protein 
purification. GST-Skp2 (WT, S256A, and S256D) was purified by using 
glutathione-S-agarose beads (Invitrogen), and then eluted with reduced 
glutathione (Fisher Scientific). 10-kDa-cutoff Centricon (Millipore) were used for 
concentrate the proteins. HA-AMPK (CA and KD) were purified by transfecting 
plasmid into 293T cells, lysate collected after 36 hours and purified with HA 
antibody followed by elution with HA peptide on the protein A/G beads. Purified 
protein concentration was determined by Bradford assay and aliquoted to 
Eppendorf tube. 
 
2.8. In vitro cell migration Assay 
Transwell inserts were placed into 24 well plates with 500μl complete DMEM 
high glucose medium on the bottom of the well. 105 cells per insert were seeded 
and cells were incubated for 6-8 hours with or without EGF 50ng/μl for migrating 
along the serum gradient. The medium was then moved and inserts were 
washed with 1XPBS, fixed with 4% paraformaldehyde on the other side of the 
bottom for 30minutes at room temperature. Q-tips were used to remove any non-
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migrated cells inside the bottom of the insert and the other side was stained with 
crystal violet reagent. The stained cells were then counted and quantified. 
 
2.9. Glucose Uptake and Lactate Production Assay 
For glucose uptake assay, cells were seeded in 60 mm plates. After 24 h, cells 
were refreshed with full serum (10% FBS) and glucose-free DMEM, while the 
complete DMEM high glucose medium served as control. After 8 hours, cells 
were treated with 50μM 2-NBDG for 30 minutes and glucose uptake rate was 
quantified by FACS analysis. For lactate production assay, cells were plated in 
24-well plate and cultured overnight in low serum medium (0.1% FBS). After 
serum starvation, cells were treated with or without EGF (50 ng/ml) for 4 hrs. 
Culture medium was then transferred from each well to Eppendorf tube. Lactate 
concentration was determined by using lactate test strips and reading under 
Accutrend Lactate analyzer (Roche). Next, cells were harvested, stained with 
trypan blue and viable cell numbers were counted directly under the microscope 
using hemocytometer. The lactate production was determined by lactate 
concentration/cells and normalized with the rate detected in the control group 
without EGF. 
 
2.10. Tube formation Assay 
HUVEC endothelial cell was used for in vitro tube formation assay. Matrigel with 
reduced growth factor (Sigma) was thawed overnight on ice in 4oC freezer. 250μl 
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matrigel was then added to 24 well plates and incubated 30min in 37oC incubator 
before seeding cell. 2x104 HUVEC cells were seeded each well and cultured with 
supernatant from indicated cultured cancer cells. After 24 hours, tube formation 
on each well was examined under bright field microscopy.    
 
2.11. In Vivo Tumorigenesis Assay 
1x 106 MDA231 cells with AMPK knockdown and Skp2 overexpression (WT, 
S256A, and S256D) were subcutaneously injected into nude mice. The tumor 
size was measured by the caliper, and the tumor volume was calculated by the 
equation: [mm3] = (length [mm]) × (width [mm]) 2 × 1/2. Xenograft tissues isolated 
were fixed in 10% formalin overnight and then embedded in paraffin. All 
manipulations on the animal are under Institutional Animal Care and Use 
Committee (IACUC) approval protocol. 
 
2.12. Patients, human materials and immunohistochemistry  
The human material study is under the approval of the Institutional Review Board 
of the Chi-Mei Medical Center in Taiwan. Immunohistochemistry was conducted 
under standard process with primary phosphor-Skp2 S256, phosphor-Akt, 
pAMPK and p27 antibodies. The secondary antibody was incubated for 30 
minutes and then developed for 5 minutes with 3-diaminobenzidine. IHC samples 
were scored manually by Dr. Chien-Feng Li under the multi-headed microscope 
as previously described (Chia-Hsin Chan 2012).  
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2.13. Statistical analysis 
All data were listed as means +/- SEM. Each experiment was conducted in three 
independent repeats. The significance is determined by two-tailed and unpaired 
student t-test. P-values < 0.05 is considered statistically significant.  
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CHAPTER 3 
RESULTS 
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3.1 AMPK is required for Akt activation under various stress 
        The PI3K/Akt pathway is an important signaling for cell proliferation and 
survival. Except for growth factors and cytokines, it can also be activated by 
many stresses, like hypoxia. However, the underlying mechanism is not clear. To 
identify possible kinases upstream of PI3K/Akt, we first applied the kinase 
inhibitors library which includes many key kinases of multiple cellular processes 
into HEK293 cells under hypoxia (Figure 3-1-1). All the inhibitors and related 
targets are listed in Table 3-1. We used LY 290034, a PI3K inhibitor as a positive 
control to inhibit Akt phosphorylation and used pAkt S473 as a readout for Akt 
activity since it has a stronger signal to minimize experimental variation. The 
result showed that HEK293 cells treated with LY290034 have less Phosphor-Akt 
S473 under hypoxia, and some inhibitors from the library also follow the trend, 
such as PDK1, PIM and receptor tyrosine kinases. Among all the candidate 
inhibitors, we noticed compound C, which is the inhibitor of AMPK, also 
suppresses Akt phosphorylation. AMPK is an energy sensor which also has been 
reported to be activated under various stresses including Hypoxia. We then 
tested and confirmed that compound C could inhibit both AMPK and Akt 
phosphorylation also in MDA231 cells (Figure 3-1-2). To further address the 
requirement of AMPK in hypoxia-induced Akt activation, we generated AMPK 
stable knockdown cells using shRNA and we found Akt phosphorylation and its 
downstream GSK3β phosphorylation were all decreased (Figure 3-1-3A), while 
restoration of AMPK into AMPK knockdown cells could rescue Akt 
phosphorylation (Figure 3-1-3B). These data suggest that AMPK is required for 
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hypoxia-induced Akt activation. To test whether AMPK is comprehensively 
required for Akt under other stress condition, we also tested glucose deprivation 
(Figure 3-1-4A) and oxidative stress H2O2 treatment (Figure 3-1-4B) and we 
found AMPK is also required for Akt activation under both conditions. The result 
suggests that there is a common mechanism for stress-induced Akt activation. 
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Figure 3-1-1 Screening of kinases in the hypoxia-induced Akt 
phosphorylation using kinase inhibitor library 
293 cells were pretreated with indicated inhibitors at 10μΜ for 2 hours and then put into 
hypoxia chamber (1% O2) for another 4 hours. Cells were lysed and subjected to 
immunoblotting with indicated antibody. The targets of each inhibitor are listed in Table 
3-1. 
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Table 3-1 List of kinase inhibitors and their targets 
 
Product Name Targets Pathway
LY294002 PI3K PI3K/Akt/mTOR
pp2 Src Protein tyrosine 
kinase
Imatinib BCR-ABL Protein tyrosine 
kinase
Nilotinib BCR-ABL Protein tyrosine 
kinase
CX-4945 CK2 DNA Repair
KU-55933 ATM DNA Repair
KU-57788 DNAPK DNA Repair
Compound C AMPK Metabolism
Quizartinib (AC220) FLT3 Angiogenesis
GNE-0877 LRRK2 Autophagy
BMS-536924 IGF1R Protein tyrosine 
kinase
PF-562271 FAK Angiogenesis
BI2536 FLK Cell Cycle
Palbociclib CDK Cell Cycle
SGI-1776 PIM JAK/STAT
ZCL278 RAC Cell Cycle
SKI II S1P Receptor GPCR&G 
Protein
Crizotinib c-Met, ALK Protein tyrosine 
kinase
CUDC-101 HDAC,HER2,
EGFR
Epigenetics
OSU-03012 PDK-1 PI3K/Akt/mTOR
K-Ras(G12C) 
inhibitor 9
Rho Cell Cycle
Nintedanib VEGFR,PDGF
R,FGFR
Protein tyrosine 
kinase
Cabozantinib FLT3, Tie-2,c-
Kit, c-
Met,VEGFR-2
Protein tyrosine 
kinase
Selumetinib MEK MAPK
SB 203580 p38, MAPK MAPK
H 89 2HCL PKA PI3K/Akt/mTOR
TWS119 GAK-3 PI3K/Akt/mTOR
Enzastaurin PKC TGF-beta/Smad
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Figure 3-1-2 Compound C inhibits both AMPK and Akt phosphorylation 
MDA-MB-231 cells were treated with or without compound C (10μM) and put into 
hypoxia chamber (1% O2) for 2 and 4 hours. Cells were lysed and subjected to 
immunoblotting with indicated antibodies. 
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Figure 3-1-3 AMPK is required for hypoxia-induced Akt phosphorylation 
and activation 
 (A) MDA-MB-231 cells with control (shLuc) and AMPKα1 knockdown were transferred 
into hypoxia chamber for 4 and 8 hours. Cell lysates were subjected to immunoblotting 
with indicated antibody. 
(B) MDA-MB-231 cells were transfected with mock (PCDNA3) and HA-AMPK (CA, KD) 
by Lipofectamine and put into hypoxia chamber (1% O2). Cell lysates were subjected to 
immunoblotting with indicated antibody. 
B 
lip
A 
lip
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Figure 3-1-4 AMPK is also required for glucose deprivation and H2O2-
induced Akt activation 
 (A) MDA-MB-231 cells with control (shLuc) and AMPKα1 knockdown were cultured in 
DMEM high glucose and no glucose medium for 1 and 2 hours. Cell lysates were 
subjected to immunoblotting with indicated antibody. 
(B) MDA-MB-231 cells with control (shLuc) and AMPKα1 knockdown were treated with 
100μΜ H2O2 for 1 and 2 hours. Cell lysates were subjected to immunoblotting with 
indicated antibody. 
B 
lip
A 
lip
40 
 
3.2. AMPK is involved in EGF-induced Akt activation and activated by 
CaMKKβ. 
Since Akt signaling is a major pathway for growth factors induced cell 
proliferation and AMPK is required for various stress induced Akt activation, we 
then checked whether AMPK is also involved in the growth factor-induced Akt 
activation. To our surprise, we found EGF-induced Akt activation is dependent on 
AMPK (Figure 3-2-1A), while under other growth factors like IGF (Figure 3-2-1B) 
and PDGF (Figure 3-2-1C), AMPK did not show any effect. Since LKB1 and 
CaMKKβ are the two major upstream kinases for AMPK activation, we next 
tested whether EGF-induced AMPK activation acted through these two known 
kinases. Our results showed that AMPK and Akt activation induced by EGF were 
impaired in CaMKKβ knockdown MDA231 cells (Figure 3-2-2A) as well as 
CaMKKβ inhibitor STO609 treated cells (Figure 3-2-2B). However, in LKB1 
knockdown cells, Akt signaling was not affected (Figure 3-2-3).  CaMKKβ is 
activated when intercellular Ca2+ level changes. To explore how CaMKKβ is 
involved in the EGF-induced Akt activation, we used Fura-2 AM, a permeable 
calcium indicator, to trace intercellular Ca2+ level upon EGF treatment and we 
found Ca2+ level was rapidly induced when cells treated with EGF for 5 minutes 
(Figure 3-2-4A). When we used a calcium chelator (BAPTA) to inhibit the 
evaluated intercellular calcium level, we also saw decreased AMPK and Akt 
activation (Figure 3-2-4B). These data suggest that EGF-induced Ca2+ level 
change activates CaMKKβ/AMPK is also important for EGF-induced Akt 
activation.  
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Figure 3-2-1 AMPK is involved in EGF but not PDGF or IGF-induced Akt 
activation 
(A) MDA-MB-231 cells with control (shLuc) and AMPKα1 knockdown were serum 
starved for 16 hours and treated with 50ng/ml EGF for 5 and 15 minutes. Cell lysates 
were subjected to immunoblotting with indicated antibody. 
(B) MDA-MB-231 cells with control (shLuc) and AMPKα1 knockdown were serum 
starved for 16 hours and treated with 100ng/ml PDGF for 5 and 15 minutes. Cell lysates 
were subjected to immunoblotting with indicated antibody. 
(C) MDA-MB-231 cells with control (shLuc) and AMPKα1 knockdown were serum 
starved for 16 hours and treated with 100 ng/ml IGF for 5 and 15 minutes. Cell lysates 
were subjected to immunoblotting with indicated antibody. 
A B 
C 
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Figure 3-2-2 CaMKKβ is required for EGF-induced AMPK/Akt activation 
(A) MDA-MB-231 cells with control (shLuc) and CaMKKβ knockdown were serum 
starved for 16 hours and treated with 50ng/ml EGF for 5 and 15 minutes. Cell lysates 
were subjected to immunoblotting with indicated antibody. 
(B) MDA-MB-231 cells were serum starved for 16 hours and treated with 50ng/ml EGF 
and 10μg/ml STO609 for 15 minutes. Cell lysates were subjected to immunoblotting with 
indicated antibody. 
 
 
 
 
A B 
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Figure 3-2-3 LKB1 is not required for EGF-induced AMPK/Akt activation 
MDA-MB-231 cells with control (shLuc) and LKB1 knockdown were serum starved for 16 
hours and treated with 50ng/ml EGF for 5 and 15 minutes. Cell lysates were subjected to 
immunoblotting with indicated antibody. 
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Figure 3-2-4 EGF-induced changes in intercellular Ca2+ 
(A) MDA-MB-231 cells were seeded in a black 96-well plate and serum starved for 16 
hours, then 2μM Fura-2AM was preloaded in calcium recording buffer for 1hour. Cells 
were washed with calcium recording buffer and treated with 50ng/ml EGF for 5 min. 
Data presented represent the relative ratio of fluorescence measured at 340 divides by 
360. *P<0.05. 
(B) MDA-MB-231 cells were serum starved for 16 hours and treated with 50ng/ml EGF 
and 10μg/ml BAPTA-2AM for 15 minutes. Cell lysates were subjected to immunoblotting 
with indicated antibody. 
 
 
*
A B 
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3.3. Akt ubiquitination is induced under hypoxia and AMPK/Skp2 are 
involved in this process. 
 The unexpected phenomenon that among three growth factors tested 
(EGF,PDGF,IGF), only EGF-induced Akt activation is dependent on AMPK also 
drives us to think what might be the factor downstream of AMPK that is unique 
for EGF signaling. We previously found that Skp2, an E3 ligase for K63-linked 
Akt polyubiquitination, activated Akt specifically upon EGF treatment but not 
under other growth factors, like IGF (Chan, 2013). Therefore, we hypothesized 
that Skp2 might serve as an AMPK downstream effector. We then use primary 
Skp2 null MEFs as well as Skp2 stable knockdown cells in MDA231 cell line to 
check whether Skp2 is also needed under stress conditions, such as hypoxia. 
Indeed, we found Skp2 deficient cells also have less Akt activation upon hypoxia 
(Figure 3-3-1A/B). Since Skp2 is an E3 ligase for Akt ubiquitination under EGF 
induction, we next examine whether Akt ubiquitination is also induced by hypoxia. 
As shown in Figure 3-3-2A, Akt ubiquitination is dramatically increased during 
hypoxia and this ubiquitination is dependent on Skp2 (Figure 3-3-2B). As we 
previously found that AMPK is important for EGF-induced Akt activation (Figure 
3-2-1A) and AMPK deficiency inhibits Akt activation. To check whether this 
impaired Akt activation is due to reduced Akt ubiquitination, we then examined 
whether AMPK inhibition affects Akt ubiquitination. This result showed that the 
induction of ubiquitination in hypoxia was inhibited when cells were treated with 
the AMPK inhibitor Compound C (Figure 3-3-3A). To further ensure this process 
is not due to the off-target effect of compound C, we also used AMPK knockdown 
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cells to confirm this phenomenon and the result also supports our previous 
observations that AMPK is required for hypoxia-induced Akt ubiquitination 
(Figure 3-3-3B). 
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Figure 3-3-1 Skp2 is also involved in hypoxia and glucose deprivation 
induced Akt ubiquitination 
(A) WT and Skp2 null MEFs were put into hypoxia chamber (1% O2) for 4 and 8 hours. 
Cell lysates were subjected to immunoblotting with indicated antibody. 
(B) MDA-MB-231 cells with control (shLuc) and Skp2 knockdown were cultured in 
DMEM high glucose and no glucose medium for 1 and 2 hours. Cell lysates were 
subjected to immunoblotting with the indicated antibody. 
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Figure 3-3-2 Skp2 E3 ligase is important for Hypoxia-induced Akt 
ubiquitination 
       (A) 293 cells were treated with hypoxia (1% O2) 4 hours and harvested for 
immunoprecipitation with Ig G control and anti-Ub antibody, followed by immunoblotting 
with Akt antibody. Input was 10% of whole cell lysate. 
(B) MDA-MB-231 cells with control (shLuc) and Skp2 knockdown were transferred into 
hypoxia chamber for 4 hours. Cell lysates were subjected to immunoprecipitation with 
Akt antibody, followed by immunoblotting with the anti-Ub and Akt antibody. Input was 
10% of whole cell lysate. 
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Figure 3-3-3 Akt ubiquitination is induced under hypoxia and AMPK is 
required for Akt ubiquitination 
(A) 293 cells were transfected with HA-Akt plasmid and put into hypoxia chamber with or 
without compound C (10μM). Cell lysates were subject to immunoprecipitation with HA 
antibody and immunoblotting with indicated antibody. 
(B) MDA-MB-231 cells with control (shLuc) and AMPKα1 knockdown were transferred 
into hypoxia chamber for 4 hours. Cell lysates were subjected to immunoprecipitation 
with Ubiquitin antibody, followed by immunoblotting with Akt antibody. Input was 10% of 
whole cell lysate.  
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3.4. AMPK directly phosphorylates Skp2 at S256  
        Our previous results indicate that there is a strong link between AMPK and 
Skp2 in stress-induced Akt activation. To test whether Skp2 is a direct substrate 
of AMPK, we purified GST-Skp2 from bacteria, as well as HA-AMPK 
constitutively activated form from 293T cells and did in vitro kinase assay. We 
found active AMPK phosphorylated Skp2 in vitro (Figure 3-4-1). To map the 
phosphorylation region, we transfected cells with active AMPK and truncated 
forms of Skp2, and we found that Skp2 was phosphorylated at the C-terminal 
truncation (205-436) but not the N-terminal truncation (1-200) (Figure 3-4-2). 
Furthermore, we used online software Sitescan to predict the phosphorylation 
site of Skp2 based on the putative substrate conserve region of AMPK (Figure 3-
4-3A). We then mutated those predicted sites and found Skp2 S256A mutant 
was no longer phosphorylated (Figure 3-4-3B/C), suggesting that AMPK 
phosphorylates Skp2 at S256. To better demonstrate the importance of this site, 
which is conserved among various species (Figure 3-4-4A), we generated Skp2 
S256 phosphor-specific antibody. This antibody was validated in cells transfected 
with the active form of AMPK and Skp2. Skp2 S256 phosphorylation could be 
detected in WT Skp2 transfected cells but not in cells transfected with Skp2 
S256A (Figure 3-4-4B). To examine the direct phosphorylation of Skp2 at S256 
by AMPK, GST-Skp2 WT or S256A mutant and HA-AMPK proteins were purified 
and in vitro kinase assay was conducted. The active form of AMPK, but not the 
AMPK kinase-dead mutant, phosphorylated Skp2 WT in vitro (Figure 3-4-5A). In 
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contrast, Skp2 S256A could not be phosphorylated by active AMPK (Figure 3-4-
5B).  
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Figure 3-4-1 AMPK phosphorylates Skp2 in vitro 
Immunoprecipitates of exogenous HA-AMPKα1 from HEK293T cells and GST-Skp2 
purified from bacteria were subjected to in vitro kinase assay followed by  
Immunoblotting.   
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Figure 3-4-2 AMPK phosphorylates Skp2 at residues after 200 
HEK293 cells transfected with Skp2 ΔN, 1-200 and the indicated HA-AMPKα (CA) 
constructs were subjected to immunoprecipitation followed by immunoblotting. 
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Figure 3-4-3 Screening of Skp2 Serine residue phosphorylated by AMPK 
(A) Skp2 putative phosphorylation site by AMPK id predicted by Scansite 
(http://scansite.mit.edu/) 
(B) HEK293 cells transfected with Skp2 WT, S256, 367, 382/383A and the indicated HA-
AMPKα (CA) constructs were subjected to immunoprecipitation followed by 
immunoblotting. 
A 
B 
C 
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(C) HEK293 cells transfected with Skp2 WT, S256A/D, and the indicated HA-AMPKα 
(CA) constructs were subjected to immunoprecipitation followed by immunoblotting. 
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Figure 3-4-4 AMPK phosphorylates Skp2 at S256 in vivo using S256 
phosphor-specific antibody 
(A) The sequence of Skp2 in different species are listed. The conserved Serine (S) 
residues at 256 in different species are highlighted. 
(B) HEK293 cells transfected with Skp2 WT, S256, and the indicated HA-AMPKα (CA) 
constructs were subjected to immunoprecipitation followed by immunoblotting. 
 
A 
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Figure 3-4-5 AMPK also phosphorylates Skp2 at S256 in vitro using S256 
phosphor-specific antibody 
 (A) Immunoprecipitates of exogenous HA-AMPKα1 (CA/KD) from HEK293T cells and 
GST-Skp2 WT purified from bacteria were subjected to in vitro kinase assay followed by 
Immunoblotting. 
(B) Immunoprecipitates of exogenous HA-AMPKα1 (CA) from HEK293T cells and GST-
Skp2 WT, S256A purified from bacteria were subjected to in vitro kinase assay followed 
by Immunoblotting.  
 
A 
B 
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3.5. S256 phosphorylation stabilizes Skp2 SCF E3 ligase complex integrity 
and is important for its E3 ligase activity 
Since Skp2 is an E3 ligase and triggers substrate ubiquitination, we next 
examined the role of S256 phosphorylation in Skp2 E3 activity. We previously 
found that Skp2 is an E3 ligase for Akt ubiquitination upon EGF treatment and 
this ubiquitination facilitates Akt membrane localization, phosphorylation, and 
activation. To examine whether AMPK mediated Skp2 S256 phosphorylation is 
important for Akt ubiquitination and activation, we performed the in vitro 
ubiquitination assay from cells transfected with Skp2 WT and S256A/D mutant 
together with HA-Akt and His-Ub. We found Akt ubiquitination was induced in WT 
and phosphor-mimic S256D Skp2 cells but not in S256A mutant cells (Figure 3-
5-1). Given that Skp2 functions as an F-box protein interacting with Skp1 and 
Cullin1 to form an SCF complex and the complex integrity are important for its E3 
ligase activity, we then tested whether Skp2 S256 phosphorylation affects Skp1 
and Cullin1 binding. We found that Cullin1 binding to Skp2 was enhanced by 
AMPK CA mutant and this binding was less in AMPK KD mutant transfected cells, 
while Skp1binding to Skp2 was slightly affected (Figure 3-5-2A), indicating that 
the kinase activity of AMPK is required for Skp2- Cul1 binding. Although the 
crystal structure of Skp2 SCF complex shows previously that Skp1 served as a 
linker between Skp2 and Cul1, It cannot exclude the possibility of Skp2- Cul1 
interaction under certain stress condition where AMPK is activated to 
phosphorylate Skp2. Therefore, we tested the function of Skp2 S256 
phosphorylation on Skp2- Cul1 binding and found that Skp2 S256A mutant no 
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longer bound to Cul1 whereas the phosphor-mimic S256D mutant still bound 
(Figure 3-5-2B). In order to know how phosphorylation of Skp2 S256 site affects 
Cullin1 binding, we modeled the 3D structure of Skp2 and Cul1 and found there 
is a putative interaction between Skp2 S256 and Cul1 K221 (Figure 3-5-3A). To 
elucidate that the protein interaction is due to negative charge provided by a 
phosphate group, we eliminated the positive charge on this site by using Cul1 
K221R mutant and found the interaction between Skp2 and Cul1 was much less 
compared to WT Cul1 (Figure 3-5-3B). All this finding suggest that Skp2 S256 
phosphorylated by AMPK is important for Skp2 E3 integrity and affected Skp2 
mediated Akt ubiquitination. 
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Figure 3-5-1 Skp2 S256 phosphorylation is important for its E3 ligase 
function. 
In vivo ubiquitination assay in HEK293T cells transfected with the indicated plasmids 
was followed by immunoblotting.  
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Figure 3-5-2 Skp2 S256 phosphorylation stabilizes Skp2 SCF complex 
integrity. 
 (A) HEK293T cells transfected with Flag-Skp2 WT, S256A/D, and the indicated HA-
AMPKα (CA) constructs were subjected to immunoprecipitation with Flag antibody and 
followed by immunoblotting. 
(B) HEK293T cells transfected with Flag-Skp2 and the indicated HA-AMPKα (CA/KD) 
constructs were subjected to immunoprecipitation with Flag antibody and followed by 
immunoblotting. 
B
A
62 
 
 
 
 
              
Figure 3-5-3 Skp2 S256 interacts with Cullin1 K221 to promote SCF 
complex stability 
(A) The potential binding pockets on the interface of Skp2-Cullin1. Skp2 is shown in 
green and Cullin1 is displayed in yellow. 
(B) HEK293T cells transfected with Flag-Cullin1 WT and K221R were subjected to 
immunoprecipitation with Flag antibody and followed by immunoblotting 
 
A 
B 
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3.6. AMPK is important for EGF-induced glucose uptake, survival under 
stress as well as glucose deprivation induced VEGF secretion through 
phosphorylating Skp2 and activating Akt. 
           To investigate the biological function of S256 phosphorylation in cells, we 
first examined whether pSkp2 S256 can be detected under physiological 
condition. We found that Skp2 S256 phosphorylation was induced in many 
conditions, including EGF treatment, hypoxia, glucose deprivation as well as 
H2O2 oxidative stress (Figure 3-6-1). AMPK is known to regulate glucose 
metabolism during energy stress. However, whether AMPK is also important for 
EGF-induced glucose uptake is not known. To test this, we examined the 
glucose uptake rate induced by EGF. We found that glucose uptake induced by 
EGF was greatly impaired in AMPK knockdown cells and when we restored Myr-
Akt (constitutively activated form) to AMPK knockdown cells, glucose uptake was 
also restored (Figure 3-6-2). Consistent with the glucose uptake rate, EGF-
induced glucose transporter Glut1 expression was also decreased in AMPK 
knockdown cells (Figure 3-6-3A). By transfecting Myr-Akt, the basal level Glut1 
expression was dramatically increased (Figure 3-6-3B). All the data suggest that 
AMPK regulates EGF-induced glucose uptake through Akt. To test whether it is 
possibly through Skp2 phosphorylation, we also restored Skp2 WT and S256 A/D 
mutant into AMPK knockdown cells and found without S256 phosphorylation, 
glucose uptake could not be restored (Figure 3-6-4) 
          To test whether AMPK is required for cell survival under stress, we treated 
cells with hypoxia and glucose deprivation and found cells with deficient AMPK 
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survived less under both conditions while Akt could rescue the survival under 
hypoxia (Figure 3-6-5A) and glucose deprivation (Figure 3-6-5B). We then 
restored AMPK knockdown cells with Skp2 and found Skp2 S256A 
phosphorylation-deficient mutant could not rescue the survival under hypoxia 
(Figure 3-6-6A) and glucose deprivation, but WT could (Figure 3-6-6B). 
           We next test whether AMPK-Skp2-Akt regulates glucose deprivation-
induced VEGF expression. We first checked the VEGF transcription and found 
MDA 231 cells with AMPKα1 knockdown transcribed less VEGF and Myr-Akt 
restored cell rescued VEGF mRNA level (Figure 3-6-7A). Moreover, MDA 231 
AMPKα1 knockdown cells with Skp2 S256A restored could not rescue VEGF 
transcription (Figure 3-6-7B). These results indicate that AMPK regulates VEGF 
transcription through Skp2 S256 phosphorylation and Akt activation. Since VEGF 
is also secreted out of the cell, we also checked the VEGF amount in the culture 
medium by Elisa. Similar to its expression, VEGF concentration in the culture 
medium was also less in AMPK knockdown cells and  rescued by Akt 
overexpression (Figure 3-6-8A) and Skp2 S256 phosphorylation (Figure 3-6-8B). 
VEGF is a growth factor that stimulates vascularization. Therefore, we examined 
the in vitro tube formation of endothelial HUVEC cells when applying the above 
mention culture medium. We found that HUVEC cells cultured with supernatant 
from AMPK knockdown cells had less tube and branch number but the 
restoration of Skp2 WT AND S256D phosphor-mimic mutant could partially 
rescue the branch number of HUVEC cells(Figure 3-6-9). 
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Figure 3-6-1 Skp2 S256 phosphorylation is induced by EGF, hypoxia, 
glucose deprivation and H2O2 treatment 
MDA-MB-231 cells with control (shLuc) and AMPKα1 knockdown were treated with EGF, 
hypoxia, glucose deprivation and H2O2. The cell lysates were subjected to 
immunoprecipitation with Skp2 antibody, followed by immunoblotting with Akt antibody.  
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Figure 3-6-2 EGF-induced glucose uptake is impaired in AMPK knockdown 
cells and can be restored by activated Akt 
MDA 231 cells with control (shLuc), AMPKα1 knockdown and Myr-Akt restored were 
starved in DMEM glucose-free medium for 4 hours and add 2NBDG for 30 min. 
Cells were then subjected to FACS analysis. Each value represented the mean ± 
SEM (n = 8 per group) in three independent experiments. **P<0.01. 
 
 
 
 
 
**
** **
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Figure 3-6-3 AMPK regulates EGF-induced Glut1 expression through Akt. 
(A) MDA-MB-231 cells with control (shLuc) and AMPKα1 knockdown were serum 
starved and treated with EGF for 15 and 30 minutes. Cell lysates were subjected to 
immunoblotting with indicated antibody. 
(B) Immunoblotting for MDA 231 cells with control (shLuc), AMPKα1 knockdown and 
Myr-Akt restored. 
 
 
B 
A 
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Figure 3-6-4 EGF-induced glucose uptake impairs in AMPK knockdown 
cells and can be restored by Skp2 S256 phosphorylation. 
MDA 231 AMPKα1 knockdown cells restored with control (Vector), Skp2 WT, S256A/D 
were starved in DMEM glucose-free medium for 4 hours and add 2NBDG for 30 min. 
Cells were then subjected to FACS analysis. Each value represented the mean ± SEM 
in three independent experiments. **P<0.01. 
 
 
 
 
 
 
 
** ****
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Figure 3-6-5 AMPK promotes cell survival under hypoxia and glucose 
deprivation through Akt 
MDA 231 cells with control (shLuc), AMPKα1 knockdown and Myr-Akt restored were 
treated with (A) hypoxia and (B) glucose deprivation. Relative cell survival rate was 
measured by trypan blue exclusive assay. Each value represented the mean ± SEM in 
three independent experiments. **P<0.01. 
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Figure 3-6-6 AMPK promotes cell survival under hypoxia and glucose 
deprivation through Skp2 S256 phosphorylation 
MDA 231 AMPKα1 knockdown cells with vector control, Skp2 WT and S256A/D 
restored were treated with (A) hypoxia and (B) glucose deprivation. Relative cell survival 
rate was measured by trypan blue exclusive assay. Each value represented the mean ± 
SEM in three independent experiments. **P<0.01. 
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Figure 3-6-7 AMPK-Skp2-Akt upregulates glucose deprivation induced 
VEGF transcription 
(A) MDA 231 cells with control (shLuc), AMPKα1 knockdown and Myr-Akt restored were 
treated with the glucose-free medium. RNA isolated from cells were subjected to RT-
PCR analysis. Each value represented the mean ± SEM in three independent 
experiments. **P<0.01. 
** ** **
** ****
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(B) MDA 231 AMPKα1 knockdown cells with vector control, Skp2 WT and S256A/D 
restored were treated with the glucose-free medium. RNA isolated from cells were 
subjected to RT-PCR analysis. Each value represented the mean ± SEM in three 
independent experiments. **P<0.01. 
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Figure 3-6-8 AMPK-Skp2-Akt upregulates glucose deprivation induced 
VEGF secretion 
(A) MDA 231 cells with control (shLuc), AMPKα1 knockdown and Myr-Akt restored (B) 
MDA 231 AMPKα1 knockdown cells with vector control, Skp2 WT and S256A/D restored 
were treated with a glucose-free medium for 8 hours and supernatant were collected for 
Elisa analysis. Each value represented the mean ± SEM in three independent 
experiments. **P<0.01. 
** ** **
** ** **
A 
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Figure 3-6-9 AMPK / Skp2 regulates glucose deprivation induced VEGF 
secretion in MDA231 cells, which affect the endothelial cell tube formation 
ability 
MDA 231 cells with control (shLuc), AMPKα1 knockdown and vector control, Skp2 WT 
and S256A/D restored were treated with a glucose-free medium for 8 hours and 
supernatant were collected for HUVEC tube formation assay. Each value represented 
the mean ± SEM in three independent experiments. **P<0.01 
**
** ** **
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3.7. Xenograft and clinical relevance of Skp2 S256 phosphorylation. 
To further determine whether AMPK is oncogenic in breast cancer, we generated 
stable knockdown of AMPK in the human breast cancer cell line MDA231 and 
then investigated the tumorigenicity of the AMPK knockdown cells in vivo by 
xenograft assay. The result showed AMPK knockdown suppressed tumor growth 
of breast cancer in vivo (Figure 3-7-1). To test whether AMPK-mediated Skp2 
S256 phosphorylation accounts for the tumorigenesis role of AMPK, we stably 
overexpressed Skp2 WT, S256A, and the S256D mutants and found 
overexpression of WT Skp2, as well as the phosphor-mimic S256D mutant, 
promoted tumor growth in vivo, whereas overexpression of phosphorylation-
deficient Skp2-S256A failed to do so (Figure 3-7-2). Hence, our data suggest that 
AMPK displays oncogenic activity in breast cancer in a manner dependent on 
phosphorylating Skp2 and activating Akt pathway. To investigate whether 
pAMPK and pSkp2 (S256) correlates with Akt activation and serves as a marker 
for poor prognosis in breast cancer patients, therefore, we assessed the 
expression of pAMPK, pSkp2 (S256), pAkt and another Skp2 substrate, p27, as 
well as their correlation in human breast cancer patients. In our breast cancer 
patient cohorts, we detected that both pAMPK, pSkp2 (S256) and pAkt were 
overexpressed in late-stage breast cancer while p27 expression was decreased 
because Skp2 ubiquitinates and promotes p27 degradation (Figure 3-7-3, Figure 
3-7-4). We used the American Joint Committee on Cancer (AJCC) stage that 
judges the clinical aggressiveness of a tumor at diagnosis. The increased 
expression of both pAMPK and pSkp2 (S256) was significantly associated with 
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pAkt expression (Figure 3-7-5, Table 3-2). Also, univariate survival analysis 
results revealed that high expression of pAMPK or pSkp2 (S256) was 
significantly predictive of breast cancer disease-specific and metastasis-free 
survival (Figure 3-7-6 and Table 3-3). Thus, our data suggest that both pAMPK 
and pSkp2 (S256) are overexpressed during breast cancer progression, thereby 
their overexpression status may serve as prognostic markers for poor survival 
outcome of breast cancer patients.  
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Figure 3-7-1 Knockdown of AMPKα1 suppresses tumor growth of breast 
cancer in vivo. 
MDA-MB-231 cells with control (shLuc) and AMPKα1 knockdown were subcutaneously 
injected into nude mice. Tumor size was measured by the caliper, and the result was 
showed as means + SEM. (n=5). **P<0.01. 
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Figure 3-7-2 Overexpression of Skp2 WT and S256D promotes tumor 
growth of breast cancer in vivo 
MDA-MB-231 cells with stable transduction of the indicated pBabe-Skp2 WT, S256A and 
S256D were subcutaneously injected into nude mice. Tumor size was measured by the 
caliper, and the result is shown as means + SEM (n=5). **P<0.01. 
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Figure 3-7-3 pSkp2 (S256) and pAMPK expression are upregulated in breast 
cancers 
Representative images of histological analysis of pSkp2 (S256), pAkt, pAMPK and p27 
staining in early (Left panel) and late-stage breast cancer (Right panel). Scale bar, 
200μm.The results were carried out by Dr. Chien-Feng Li. 
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Figure 3-7-4 Overexpression of pSkp2 (S256), pAMPK and in an advanced 
stage of breast cancer patient 
Box plot represents pSkp2 (S256), pAMPK and pAkt expression in different stageS of 
breast cancer patient. The results were carried out by Dr. Chien-Feng Li. **P<0.01. 
  
 
 
** ** 
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Figure 3-7-5 pAMPK and pAkt expression both correlate with pSkp2 (S256) 
in breast cancer patients 
Scatter plots of pSkp2 (S256) expression versus pAMPK and pAkt expression in breast 
cancer patient were presented. The results were carried out by Dr. Chien-Feng Li. 
  
   
 
r=0.374, p<0.001
r=0.282, p<0.001
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Figure 3-7-6 Overexpression of pSkp2 or pAMPK predicts poor survival 
outcome of Breast cancer patients 
 (A) (B) Kaplan-Meier plots showed that high expression of pAMPK (A) or pSkp2 (S256) 
(B) was significantly predictive of disease-specific survival.  
(C) (D) Kaplan-Meier plots showed that high expression of pAMPK (A) or pSkp2 (S256) 
(B) was significantly predictive of local recurrence-free survival. The results (A–D) were 
carried out by pathologist Dr. Chien-Feng Li. 
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Table 3-2 Associations between pSkp2 expressions with important clinic 
pathologic variables and pAkt, p27, pAMPK expression 
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Table 3-3 Univariate survival analysis 
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CHAPTER 4 
DISCUSSION AND FUTURE DIRECTIONS 
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         In our kinase inhibitors screening data as showed in Figure 3-1-1, we 
noticed that PDK1 inhibitor OSU-03012, PIM inhibitor SGI-1776, a Src inhibitor 
as well as inhibitors that target cell membrane receptors: IGF-1R, VEGFR, 
PDGFR, FGFR, and c-MET can also inhibit Akt phosphorylation under hypoxia. 
PDK1 is a directed kinase to trigger T308 phosphorylation on the plasma 
membrane, followed by S473 phosphorylation in the cytoplasm. It is not 
surprising if PDK1 inhibitor could abolish Akt S473 phosphorylation under 
hypoxia. Activation of growth factor receptors usually leads to activation of Src 
and PI3K. All of the inhibitors target those kinases could inhibit Akt activation 
under hypoxia, suggesting that hypoxia-induced Akt activation also acts through 
cell membrane growth factor receptors. AMPK-mediated Skp2 phosphorylation 
triggers Akt ubiquitination and activation. This route still requires upstream 
receptors and PI3K. However, how hypoxia induces the membrane growth factor 
receptors without ligand binding needs further investigation. The future direction 
could focus on whether hypoxia affects receptor dimerization, aggregation or 
internalization. 
         AMPK is activated by both LKB1 and CAMKKβ. LKB1 mediated AMPK 
activation suppresses cell growth in certain cancers, such as NSCLC and 
cervical cancer(Shaw 2009). However, inhibition of the CAMKKβ  decreases cell 
proliferation, migration and invasion in prostate cancer cells (Racioppi 2013). In 
addition, CaMKKβ is amplified in prostate cancer, invasive breast cancer, and 
ovarian cancer as shown in the TCGA data set (Ethan Cerami 2012, Gao J 2013). 
These observations support the oncogenic effect of CaMKKβ. Therefore, its 
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downstream substrate, AMPK, is likely involved in the oncogenic functions of 
CaMKKβ.  Interestingly, we found that CaMKKβ deficient cell also had decreased 
Akt activation under EGF treatment, which is similar to what happened in AMPK 
knockdown cells, suggesting the CaMKKβ/AMPK might promote tumor 
progression through Akt activation. In contrast, LKB1 has not involved EGF-
induced AMPK and Akt activation. Therefore, our findings indicate that oncogenic 
role of AMPK is through Akt activation and may largely drive by CaMKKβ under 
EGF treatment while LKB1 might only keep the basal AMPK activation for energy 
balance in breast cancer cell line MDA-MB-231. Our findings also suggest that 
AMPK targeting might be therapeutically beneficial for advanced breast cancer. 
Future directions can also focus on the role of CaMKKβ in breast cancer 
progression, either by xenograft mouse model or tissue-specific knockout of 
CaMKKβ.  
          EGF binds to its membrane receptor EGFR and activates it through 
receptor dimerization. Downstream of EGFR include MAPK, PI3K/Akt, PLCγ and 
STAT-mediated pathway, which ultimately promote many cellular events 
including cell proliferation, migration, differentiation, and anti-apoptosis. We 
surprisingly found that EGF also activated AMPK within a short time (~2 min). 
Also, AMPK deficient cell displayed decreased EGF-induced Akt activation. This 
observation brings AMPK to the traditional EGF-PI3K/Akt pathway. Moreover, we 
found AMPK activated by EGF through CaMKKβ but not LKB1. EGF-induced 
AMPK activation is rapid and without any changes in ATP level but intercellular 
Ca2+ level. Therefore, our data suggest that CaMKKβ triggers rapid AMPK 
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activation in a Ca2+ dependent manner while LKB1 activates AMPK when cell 
face decreased AMP/ADP: ATP ratio. Activated EGFR activates PLCγ to 
catalyze PIP2 to generate secondary message DAG and IP3. IP3 then binds to 
its receptor IP3R, a calcium channel on the membrane of ER, which induces 
calcium release from (endoplasmic reticulum) ER calcium stores and increases 
intercellular calcium level. Calcium binds to the protein calmodulin and activates 
CaMKK. Our findings not only indicate the rapid changes of intercellular calcium 
level is important for EGF-induced Akt signaling, but also brings AMPK as a new 
component of EGF-PI3K/Akt pathway.  The future direction would be to confirm 
and further explore the importance of AMPK in EGF-PI3K/Akt pathway. Whether 
both AMPK and PI3K are needed for Akt activation? Could AMPK rescue Akt 
activity if PI3K is inactivated? Moreover, many studies have revealed that EGFR 
is overexpressed in MDA231 cells, but EGFR targeting has limited effect in 
clinical trials due to the resistant mechanism. It will be also worthy of examining 
whether AMPK activation may account for one of the resistance mechanism for 
EGFR targeting therapy. It is possible that targeting AMPK together with EGFR is 
beneficial for triple negative breast cancer treatment.  
           PI3K/Akt is a classic pathway to promote cell proliferation, survival and 
inhibit apoptosis. In contrast, AMPK’s role in cancer is context-dependent. 
However, both of them are activated when the cell faces various stress like 
hypoxia, oxidative stress, and glucose deprivation. AMPK and Akt share many 
common substrates but different outcomes. The role of AMPK in Akt regulation is 
not clear at the current stage. Reports indicate that AMPK can either activate or 
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inhibit Akt. However, those studies were performed under AICAR and metformin 
treatment which might have many other off-target effects. Importantly, our study 
uncovered a novel mechanism that AMPK activates PI3K/Akt pathway by 
phosphorylating Skp2 and promoting Akt ubiquitination. It improves our current 
understanding of relationships of AMPK and Akt. Importantly, it indicates that as 
the tumor progresses and encounters limited resources, activation of AMPK is 
important to phosphorylate Skp2 and turn on Akt survival pathway to resist 
immediate death. However, we cannot exclude other Skp2 E3 ligase substrates 
might contribute to increasing survival. In the future, it may be worth to test other 
Skp2 substrates, given that Skp2 also ubiquitinates and promotes degradation of 
p27 (Keiko Nakayama 2004, Uta Kossatz 2004). Our result in the human breast 
cancer patient sample also showed downregulation of p27 and its correlation with 
poor survival outcome. It is possible that Skp2 S256 phosphorylation targeting 
may also affect p27 or other downstream substrates due to its defect E3 ligase 
activity.  We could test whether, under certain stimuli, AMPK activation leads to 
more Skp2-mediated p21 or p27 ubiquitination in cancer cells to regulates the 
cell cycle. 
         Ubiquitination either leads to protein degradation or promote signaling 
transduction depending on how the ubiquitin is linked. While K48 linked 
ubiquitination targets protein for proteasome degradation, K63 linked 
ubiquitination have important functions in signaling transduction. Previous work in 
our lab revealed that K63 linked Akt ubiquitination is important for its activation by 
growth factors stimulation. Our finding that Akt ubiquitination was greatly induced 
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by hypoxia provides a better picture of how Akt is activated under stress. K63 
linked polyubiquitination may recruit other components to facilitate Akt membrane 
localization. One of the putative molecules that may be relevant is Ubl4A, an 
ubiquitin-like protein that directly binds to actin filaments. A Recent study has 
shown that upon insulin treatment, Ubl4a binds to actin related protein 2/3 and 
accelerates actin branching and Akt membrane localization. It provides a missing 
link of Akt activation under insulin. It also gives us a hint that there might be other 
adaptor proteins exist to facilitate Akt membrane localization and activation under 
stress, like hypoxia. Akt ubiquitination may be critical to recruiting various 
adaptors for Akt membrane localization and activation under the diverse situation.  
         Skp2-SCF complex consists of an F-box protein Skp2, an adaptor Skp1, 
and Cul1. Crystal structure of Skp2-SCF (Figure 4-1) revealed that Skp1 act as a 
linker to bridge both Skp2 and Cul1. However, the crystal structure used a 
truncated F-box domain of Skp2 instead of full-length Skp2(Ning Zheng 2002). 
Skp2 contains an F-box domain which binds Skp1 and an LRR domain which is 
important for substrate recognition. The S256 residue is located inside the LRR 
domain. We found that Skp2 S256 phosphorylation is important for Cul1 binding 
and Akt ubiquitination. It suggests Skp2 may also interact with Cul1 to keep the 
SCF complex integrated and more functional.  However, whether Skp1 is 
required for Cul1 and Skp2 interaction is still not clear. To this end, we could 
examine the interaction of Skp2 and Cul1 without Skp1. The crystal structure with 
Skp1, Cul1, and full-length Skp2 will be beneficial to examine the interaction 
between Skp2 and Cul1. It is also possible that Skp2 S256 phosphorylation may 
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affect the substrate recognition. Previous studies showed that Cks1 (CDK 
subunit 1) is required for Skp2 to recognize phosphorylated p27(Ganoth D 2001). 
Therefore, the interaction between Skp2 and Cks1 or Akt can also be tested for a 
better understanding of the function of Skp2 S256 phosphorylation.   
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Figure 5 Crystal structure of Skp2-SCF complex 
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          Our study also showed that expression level of Skp2 S256 phosphorylation 
was correlated with AMPK and Akt phosphorylation and poor survival outcomes 
in breast cancer patients. These results indicate the in vivo relevance of AMPK in 
breast cancer progression. Our findings also showed the pronounced effect of 
AMPK and Skp2 S256 phosphorylation in mouse xenograft models. It suggests 
that AMPK and Skp2 S256 phosphorylation targeting might be a promising 
strategy for inhibiting breast cancer progression. In order to further dissect the 
significance of Skp2 S256 phosphorylation in cancer progression, we can use 
MMTV/Skp2 WT and S256A/D transgenic mice as a tool to study whether the 
phosphorylation is important to increase tumor incidence. We can also use Skp2 
WT and S256A/D knock-in mice and cross with PTEN conditional knockout mice 
to further address the oncogenic role of Skp2 S256 phosphorylation.  Meanwhile, 
we can also generate small molecular inhibitors to target Skp2 S256 
phosphorylation and evaluate its efficacy in blocking tumor progression. 
          Another interesting finding of our work is that AMPK mediated Skp2 
phosphorylation and Akt activation is involved in the glucose deprivation induced 
VEGF secretion from cancer cells to the culture medium. When we apply the 
supernatant to the endothelial cell grown in matrix-gel, it will cause the formation 
of tube-like structure. These results suggest that as tumor quickly expands and 
encounters short supplies of glucose, AMPK might be also important for cancer 
cells to modify the tumor microenvironment by promoting angiogenesis and 
obtain more glucose in the blood vessel. Future work is needed to examine 
angiogenesis in vivo by detecting markers for vascularization within xenograft 
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tissue. By doing this, we can potentially prove the role of AMPK and Skp2 
phosphorylation in angiogenesis and promote tumor progression. Since 
angiogenesis will facilitate tumor migration from the original location to distal 
organs, we will also check the role of AMPK and Skp2 S256 phosphorylation in 
metastasis.  
           In summary, our study shows that AMPK is required for various stress 
induced Akt activation and promotes cell survival, including hypoxia and glucose 
deprivation. AMPK is also important for EGF-induced Glut1 expression and 
glucose uptake, as well as glucose deprivation induced VEGF expression and 
secretion. AMPK directly phosphorylates Skp2 at S256 residue and this 
phosphorylation is important for Skp2 SCF complex integrity and E3 ligase 
activity to ubiquitinate and activates Akt upon various stresses, as well as EGF 
growth factor stimulation. The Skp2 phosphorylation status is important for tumor 
progression and correlated with poor survival of breast cancer patient. The 
working model of my study is shown in Figure 4-2. 
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Figure 4-6 Hypothetic model of the role of pAMPK in Stress and EGF-
induced Akt activation and tumorigenesis. 
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